The shift from batch to continuous processing represents one of the most significant evolutionary steps in biopharmaceutical manufacturing. Among the unit operations being reimagined for continuous operation, chromatography — the workhorse of downstream purification — has undergone particularly rapid transformation. Continuous chromatography moves beyond the stop-and-start nature of traditional packed-bed batch processes, enabling uninterrupted loading, washing, elution, and regeneration in a steady-state flow. This approach delivers measurable gains in productivity, product quality, cost efficiency, and operational flexibility, making it an increasingly essential technology for manufacturers of monoclonal antibodies, vaccines, gene therapies, and other complex biologics.

What Is Continuous Chromatography?

At its core, continuous chromatography is a method in which the separation process occurs continuously rather than in discrete, sequential steps. In a typical batch chromatography cycle, a column is loaded with feed material until saturation, then washed, eluted, and regenerated before the next cycle can begin. These dead times between cycles limit throughput and create process variability. Continuous chromatography, by contrast, uses multiple columns or a rotating column setup — such as simulated moving bed (SMB) or multicolumn continuous chromatography (MCC) systems — to overlap these steps. While one column is loading, another is washing, eluting, or regenerating. The result is near‑constant use of the resin and a steady outflow of purified product.

Two dominant configurations have emerged in bioprocessing:

  • Simulated Moving Bed (SMB): Originally developed for small‑molecule separations, SMB uses a series of columns connected in a loop with periodic switching of inlet and outlet ports to simulate countercurrent movement between solid and liquid phases. This provides high resolution and very efficient resin utilization, especially for binary separations such as enantiomers. In bioprocessing, SMB is adapted for capture and polishing steps where the target binds tightly to the resin.
  • Multicolumn Continuous Chromatography (MCC): MCC systems, such as those from ChromaTan, GE Healthcare (now Cytiva), and Novasep, typically use 2–8 columns. A popular variant is periodic counter‑current chromatography (PCC), where columns are loaded sequentially and then moved through wash, elution, and regeneration steps in a staggered fashion. MCC is particularly well suited for large‑scale capture of monoclonal antibodies using Protein A resin.

Both approaches maintain a steady state of operation, eliminating non‑productive periods and allowing the process to run for extended durations — sometimes days or weeks — without interruption. This fundamental change in operation yields a host of benefits that are reshaping downstream bioprocess economics.

Key Advantages of Continuous Chromatography

1. Dramatically Increased Productivity

The most immediate benefit of continuous chromatography is higher volumetric productivity. Because columns are loaded to near breakthrough capacity while other columns handle non‑loading steps, the resin is used at or near its full dynamic binding capacity at all times. In batch mode, a column is loaded only until a safety margin below breakthrough is reached, leaving a significant portion of binding capacity unused. Continuous systems push loading much closer to the breakthrough point, often achieving 20–40% higher resin utilization. Combined with elimination of downtime between cycles, this can result in a 2‑ to 5‑fold increase in throughput per unit of resin per unit time.

2. Reduced Buffer and Water Consumption

Continuous chromatography processes operate at lower buffer volumes than their batch counterparts. Because elution and regeneration are performed on separate columns while loading continues, the system avoids the waste inherent in batch cycling — where entire column volumes of buffer are discarded between runs. For a typical monoclonal antibody capture process, continuous chromatography can reduce buffer consumption by 30–50%, and in some cases even more for polishing steps. This translates directly into lower raw material costs, reduced wastewater, and smaller buffer preparation and storage requirements.

3. Improved Product Quality and Consistency

Steady‑state operation leads to more uniform product quality. In batch chromatography, the product experiences changing conditions over the course of a cycle — initial high binding, then saturation, then elution gradients. Continuous processes maintain constant flow rates, buffer compositions, and residence times across the entire run. This consistency reduces variability in product aggregation, clipping, or post‑translational modifications. Moreover, continuous systems often incorporate real‑time monitoring of critical quality attributes (e.g., UV absorbance, pH, conductivity) with automated feedback control, allowing immediate adjustments that keep the product within specification. The result is a more homogeneous final product, which is especially important for biologics with narrow therapeutic windows.

4. Smaller Equipment Footprint and Lower Capital Costs

Because continuous chromatography achieves the same purification capacity with less resin and smaller columns, the overall equipment size can be reduced. A single continuous system with three or four small columns can often replace several large batch columns. This downsizing lowers the capital investment for columns, packing equipment, and associated hardware. It also reduces the cleanroom footprint, which is particularly valuable in new facility designs aiming for modular, flexible manufacturing. For contract development and manufacturing organizations (CDMOs), the smaller footprint enables faster changeovers between products and more efficient use of expensive classified space.

5. Enhanced Scalability and Process Intensification

Continuous chromatography scales more predictably than batch. Batch scale‑up often requires extensive re‑optimization of column dimensions, flow rates, and gradient profiles because column length‑to‑diameter ratios change. In continuous systems, the fundamental unit is a small column operated at the same linear velocity and bed height as the lab‑scale unit; scale‑up is achieved by adding more columns or running longer durations rather than increasing column size. This allows seamless transfer from development to commercial production without re‑validation of the separation itself. Additionally, continuous chromatography integrates naturally with upstream continuous perfusion bioreactors, enabling fully continuous end‑to‑end manufacturing — a long‑standing goal of the bioprocess industry.

6. Better Process Control and Automation

Modern continuous chromatography platforms are equipped with advanced process analytical technology (PAT) and control software. Real‑time sensors monitor column status, product concentration, and impurities. Adaptive control algorithms adjust flow rates, switching times, and elution gradients to maintain optimal performance even as feed quality fluctuates. This level of control not only improves robustness but also supports the implementation of real‑time release testing, where product release decisions are based on continuous monitoring data rather than end‑product testing. For regulatory agencies such as the FDA, these control strategies align with the Quality by Design (QbD) initiative and can streamline the approval process.

Applications in Bioprocessing

Monoclonal Antibodies and Fc‑Fusion Proteins

The most widespread application of continuous chromatography today is the capture of monoclonal antibodies (mAbs) using Protein A resin. Protein A is expensive, so maximizing its utilization is economically compelling. Continuous Protein A capture using PCC systems has been adopted by several innovator companies and CDMOs for both clinical and commercial manufacturing. Studies show that continuous Protein A can reduce resin costs by 30–50% while maintaining high yield (>95%) and product quality. The technology is also applied to polishing steps, such as ion exchange and hydrophobic interaction chromatography, where continuous operation improves separation of aggregates and charge variants.

Vaccines and Viral Vectors

Continuous chromatography is gaining traction in the purification of vaccines and advanced therapy medicinal products (ATMPs), including viral vectors for gene therapy. These biologics are often larger, more fragile, and present in lower titers than mAbs. Batch chromatography can lead to significant yield losses due to shear forces, denaturation, or inefficient binding. Continuous systems with gentle flow paths and shorter residence times can improve yields and preserve particle integrity. For example, continuous ion‑exchange chromatography has been used for the purification of adeno‑associated virus (AAV) vectors, achieving higher recovery while maintaining infectivity. Similarly, vaccine manufacturers are exploring continuous simulated moving bed chromatography for both inactivated and live‑attenuated virus purification.

Plasma Derived Proteins and Anticoagulants

Fractionation of plasma proteins — such as albumin, immunoglobulins, and clotting factors — has traditionally relied on cold ethanol precipitation and batch chromatography. Continuous chromatography offers opportunities to improve yield, purity, and process economy for these high‑volume products. The ability to run for extended periods without interruption is especially beneficial for plasma‑derived therapeutics, where the feed volume is large and the value of each gram of protein is high.

Polishing of Bioconjugates and Biosimilars

As the biosimilar market matures, manufacturers are under pressure to reduce costs while meeting strict similarity requirements. Continuous chromatography enables tighter control over critical quality attributes, such as glycan profiles and charge variants, which are often the focus of comparability exercises. It also provides flexibility to run multiple polishing steps in series or to recycle off‑spec material, improving overall process yield.

Challenges and Considerations

System Complexity and Validation

Continuous chromatography systems are inherently more complex than batch systems. They require multiple columns, precise switching valves, sophisticated control software, and robust automation. The increased number of components introduces more potential failure points, and validation of the entire system — including the control algorithms for column switching — can be more demanding. Process development teams need expertise in both chromatography and automation to set up and optimize continuous runs.

Resin and Column Considerations

Continuous operation puts additional stress on the resin and column hardware. Resins must be robust enough to withstand thousands of cycles without degradation in capacity or selectivity. Pre‑packed, ready‑to‑use columns are commonly employed to avoid the variability of packing in‑house, but these columns must be verified for long‑term mechanical stability at the flow rates and switching frequencies used in continuous processes. Additionally, resin fouling can become more pronounced over extended runs if feed contains particulates or aggregates; effective upstream clarification is essential.

Regulatory Acceptance

While regulatory agencies have expressed support for continuous manufacturing, the path to approval for a continuous chromatography process can require more extensive data than for a batch process. Manufacturers must demonstrate that the continuous system produces consistent product quality over extended run durations, including the effects of column aging, resin reuse, and potential carryover between cycles. The FDA’s 2019 guidance on Process Validation and its emerging guidance on continuous manufacturing provide frameworks, but companies often need to engage in early dialog with regulators to align on validation strategies and lifecycle management.

Integration with Upstream and Downstream Operations

To realize the full benefits of continuous chromatography, it must be integrated into a holistic continuous bioprocess. Upstream perfusion bioreactors supply a steady feed of cell culture fluid, but fluctuations in product titer, cell density, or impurity levels can challenge the downstream purification steps. Similarly, the purified product stream must be handled by downstream unit operations — such as viral inactivation, ultrafiltration, or formulation — which may themselves be batch or continuous. Buffer supply and waste management also need to be coordinated. Successful implementation requires a systems‑engineering approach and often a change in facility layout to accommodate the smaller, but more interconnected, equipment.

The adoption of continuous chromatography is accelerating, driven by the twin pressures of cost reduction and quality improvement. Several trends are shaping its evolution:

  • Digital Twins and Model‑Based Optimization: Combining mechanistic models of chromatography (e.g., the general rate model) with machine learning is enabling in silico optimization of continuous processes. Digital twins allow process developers to simulate thousands of operating conditions and select the best switching scheme, flow rates, and column configurations without exhaustive lab experimentation.
  • Single‑Use Continuous Systems: The rise of single‑use technology is extending into continuous chromatography. Pre‑sterilized, single‑use columns and flow paths reduce cross‑contamination risks and eliminate cleaning validation, making continuous chromatography more accessible for multiproduct facilities and small‑scale production.
  • Integration with Real‑Time Monitoring and Release: Advances in online analytics — such as multi‑angle light scattering, mass spectrometry, and automated ELISA — are enabling near‑complete characterization of the product stream in real time. Combined with continuous chromatography, this opens the door to real‑time release, reducing lead times from weeks to hours.
  • Automated Continuous Purification Trains: The ultimate vision is a fully automated, end‑to‑end continuous purification train, where the output of continuous chromatography feeds directly into continuous viral inactivation (using continuous flow reactors), continuous ultrafiltration/diafiltration, and continuous formulation. Several research groups and companies are demonstrating integrated systems at pilot scale, with the goal of a fully “process‑intensified” plant that operates around the clock with minimal human intervention.
  • Regulatory Guidance and Standards: As more products are manufactured using continuous chromatography, regulatory agencies are developing specific guidance. The FDA’s Emerging Technology Team and the ICH’s Q13 guidance on Continuous Manufacturing of Drug Substances and Drug Products provide frameworks for process description, batch definition, and regulatory submissions. Over time, these standards will reduce the validation burden and encourage wider adoption.

Conclusion

Continuous chromatography is no longer a niche technique reserved for academic research or small‑molecule separations. It has matured into a robust, scalable, and economically advantageous platform for downstream bioprocessing of the most complex biopharmaceuticals. The benefits — higher productivity, reduced costs, improved product quality, smaller footprints, and better process control — are being realized by a growing number of manufacturers across the product spectrum, from monoclonal antibodies to vaccines and viral vectors.

While challenges remain in system complexity, validation, and integration, the trajectory is clear. With continued advances in automation, sensor technology, and regulatory science, continuous chromatography will become a standard building block of modern biomanufacturing. Companies that invest now in understanding and implementing this technology will be well positioned to achieve the operational excellence and flexibility demanded by the next generation of biologic therapeutics. For more detailed case studies and technical comparisons, resources such as BioProcess International and the National Center for Biotechnology Information offer extensive peer‑reviewed literature on the design and performance of continuous chromatography systems in commercial bioprocessing.